N
Nicolas Penel
Researcher at university of lille
Publications - 523
Citations - 15939
Nicolas Penel is an academic researcher from university of lille. The author has contributed to research in topics: Medicine & Sarcoma. The author has an hindex of 58, co-authored 449 publications receiving 11288 citations. Previous affiliations of Nicolas Penel include Institut Gustave Roussy & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurélien Marabelle,Dung T. Le,Paolo A. Ascierto,Anna Maria Di Giacomo,Ana De Jesus-Acosta,Jean Pierre Delord,Ravit Geva,Maya Gottfried,Nicolas Penel,Aaron R. Hansen,Sarina Anne Piha-Paul,Toshihiko Doi,Bo Gao,Hyun Cheol Chung,Jose A. Lopez-Martin,Yung-Jue Bang,Ronnie Shapira Frommer,Manisha H. Shah,Razi Ghori,Andrew K. Joe,Scott K. Pruitt,Luis A. Diaz +21 more
TL;DR: The study demonstrates the clinical benefit of anti-programmed death-1 therapy with pembrolizumab among patients with previously treated unresectable or metastatic MSI-H/dMMR noncolorectal cancer.
Journal ArticleDOI
Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study
Nicolas Penel,Binh Bui,Jacques-Olivier Bay,Didier Cupissol,Isabelle Ray-Coquard,Sophie Piperno-Neumann,Pierre Kerbrat,C. Fournier,Sophie Taïeb,Marta Jimenez,Nicolas Isambert,Frederic Peyrade,Christine Chevreau,Emmanuelle Bompas,Etienne Brain,Jean-Yves Blay +15 more
TL;DR: Weekly paclitaxel at the dose schedule used in the current study was well tolerated and demonstrated clinical benefit, and anemia and fatigue were the most frequently reported toxicities.
Journal ArticleDOI
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.
Isabelle Ray-Coquard,Jean-Yves Blay,Antoine Italiano,Axel Le Cesne,Nicolas Penel,Jianguo Zhi,Florian Heil,Ruediger Rueger,Bradford Graves,Meichun Ding,David Geho,Steven A. Middleton,Lyubomir T. Vassilev,Gwen Nichols,Binh Bui +14 more
TL;DR: In this article, the authors report a proof-of-mechanism study of RG7112, a small-molecule MDM2 antagonist, in patients with chemotherapy-naive primary or relapsed well-differentiated or dedifferentiated liposarcoma who were eligible for resection.
Journal ArticleDOI
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.
Maud Toulmonde,Nicolas Penel,Julien Adam,Julien Adam,Christine Chevreau,Jean-Yves Blay,Axel Le Cesne,Emmanuelle Bompas,Sophie Piperno-Neumann,Sophie Cousin,Thomas Grellety,Thomas Ryckewaert,Alban Bessede,François Ghiringhelli,Marina Pulido,Antoine Italiano +15 more
TL;DR: It is found that PD-1 inhibition has limited activity in selected STS and GIST, and may be explained by an immunosuppressive tumor microenvironment resulting from macrophage infiltration and IDO1 pathway activation.
Journal ArticleDOI
An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)
Bernd Kasper,C. Baumgarten,José María Díaz García,S. Bonvalot,Rick L. Haas,Florian Haller,Peter Hohenberger,Nicolas Penel,Christina Messiou,W.T.A. van der Graaf,Alessandro Gronchi +10 more
TL;DR: New findings regarding the prognostic value of mutational analysis in desmoid-type fibromatosis patients and new systemic treatment options are focused on.